Enovis

Enovis's stock rose about 11% after the Centers for Medicare & Medicaid Services withdrew announced reimbursement cuts for Enovis' non-invasive bone growth stimulators. The decision temporarily relieves regulatory pressure on the product segment and triggered the price move. » Más en de.investing.com

Enovis shares fell to a 52-week low of about $20.84 but, according to InvestingPro, are undervalued with a fair value of $29.81. Analysts expect a return to profitability, and InvestingPro includes Enovis among the most undervalued stocks. The company reported Q1 2026 adjusted EPS of $0.89 (expectation $0.81) and revenue of $589 million (expectation $573.02 million), launched the DonJoy Spinamic Hybrid Scoliosis Brace in the U.S., and shareholders approved an expansion of the omnibus incentive plan. » Más en de.investing.com

Enovis Corp shares fell to a 52-week low of $20.96 (currently $20.87) and dropped more than 10% last week; year-to-date the stock is down about 31.52%. Despite the decline, Enovis beat expectations in Q1 2026 with adjusted EPS of $0.89 (expectation $0.81) and revenue of $589 million (forecast $573.02 million). InvestingPro rates the stock as significantly undervalued and points to analyst expectations of a return to profitability later this year. At the annual general meeting, shareholders approved the issuance of 3,650,000 additional common shares and raised the annual compensation cap for external board members. » Más en de.investing.com